Literature DB >> 8640162

The composition of CD34 subpopulations differs between bone marrow, blood and cord blood.

G Fritsch1, M Stimpfl, M Kurz, D Printz, P Buchinger, G Fischmeister, P Hoecker, H Gadner.   

Abstract

Our previous data obtained by flow cytometry and by clonogenic assay had consistently shown a lower cloning efficiency of hematopoietic progenitor cells in bone marrow (BM) compared to those in blood (PB) or in cord blood (CB). Also, recent clinical reports have described more rapid reconstitution after PB than after BM transplantation. We have applied two- or three-color flow cytometric analysis using monoclonal antibodies directed against the stem- and progenitor cell antigen CD34, in combination with other cell surface markers. We report significant differences in the composition of progenitor cells contained in BM (238 specimens from 53 healthy donors and from patients in remission), PB (301 samples from 92 patients with or without cytokine support) and CB (n = 37). Leukapheresis products (Pher, n = 69) were included in the study as well as positively selected CD34+ cells obtained from BM (BMsel, n = 2), PB (PBsel, n = 28) and CB (CBsel, n = 5). We used monoclonal antibodies directed against CD7, CD19, CD34, CD38, CD45RA and glycophorin A. The highest proportion of CD34+ cells (in % of the MNC) was found in BM (mean 5.37% +/- 4.5). In the other sources, the mean values were 1.79% +/- 2.46 (PB), 1.48% +/- 1.81 (Pher) and 1.1% +/- 1.69 (CB). However, BM was the only source in which a considerable proportion of the CD34+ cells coexpressed the B cell antigen CD19 (mean 30.1%, median 28, range 0 to 84%). The amount of earlier myeloid progenitors as determined by their non-expression of the CD45RA antigen was lowest among BM CD34+ cells (26.7% +/- 16.6). In the other sources, the respective values were 57.5% +/- 17.9 (PB), 63.6% +/- 13.9 (Pher) and 70.4% +/- 16.1 (CB). These results were confirmed by subtype analyses of the CD34+ cells positively selected from the three sources. Enrichment showed minor CD34+ subpopulations to be identified. The mean proportions of B cell progenitors were 0.11% +/- 0.24 (PBsel) and 1.3% +/- 1.42 (CBsel) of the CD34+ cells. The CD34+ cells from all cell sources coexpressed GPA (median 0.15%, range 0 to 1.8%) and CD7 (median 0.25%, range 0 to 1.2%). The proportion of CD38- cells ranged from 0.7 to 4% of the CD34+ MNC. Thus, despite higher CD34 counts in BM, the relative proportions of myeloid progenitors are higher in PB and in CB. This suggests that, if timely reconstitution depends on the number of CD34+ cells transplanted, the mean number of "stem cells' (SC) required is 1.4-fold (for myeloid cells) or 2.2-fold (for earlier myeloid cells) higher for BM than for PB.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8640162

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  7 in total

1.  Pan-myeloid Differentiation of Human Cord Blood Derived CD34+ Hematopoietic Stem and Progenitor Cells.

Authors:  Aditi Bapat; Nakia Keita; Shalini Sharma
Journal:  J Vis Exp       Date:  2019-08-09       Impact factor: 1.355

2.  Single Versus Dual Platform Analysis for Hematopoietic Stem Cell Enumeration Using ISHAGE Protocol.

Authors:  Rahul Naithani; Nitin Dayal; Gaurav Dixit
Journal:  Indian J Hematol Blood Transfus       Date:  2016-12-01       Impact factor: 0.900

3.  No evidence of clonal dominance after transplant of HOXB4-expanded cord blood cells in a nonhuman primate model.

Authors:  Korashon L Watts; Brian C Beard; Brent L Wood; Grant D Trobridge; R Keith Humphries; Amie B Adams; Veronica Nelson; Hans-Peter Kiem
Journal:  Exp Hematol       Date:  2014-04-02       Impact factor: 3.084

4.  Multi-color immune-phenotyping of CD34 subsets reveals unexpected differences between various stem cell sources.

Authors:  J Dmytrus; S Matthes-Martin; H Pichler; N Worel; R Geyeregger; N Frank; C Frech; G Fritsch
Journal:  Bone Marrow Transplant       Date:  2016-04-04       Impact factor: 5.483

5.  Correction of beta-thalassemia major by gene transfer in haematopoietic progenitors of pediatric patients.

Authors:  Emanuela Anna Roselli; Riccardo Mezzadra; Marta Claudia Frittoli; Giulietta Maruggi; Erika Biral; Fulvio Mavilio; Fabrizio Mastropietro; Antonio Amato; Giovanni Tonon; Chiara Refaldi; Maria Domenica Cappellini; Marco Andreani; Guido Lucarelli; Maria Grazia Roncarolo; Sarah Marktel; Giuliana Ferrari
Journal:  EMBO Mol Med       Date:  2010-08       Impact factor: 12.137

6.  Estimation of the haematological toxicity of minor groove alkylators using tests on human cord blood cells.

Authors:  M Ghielmini; G Bosshard; L Capolongo; M C Geroni; E Pesenti; V Torri; M D'Incalci; F Cavalli; C Sessa
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

7.  Chronic myelomonocytic leukaemia stem cell transcriptomes anticipate disease morphology and outcome.

Authors:  Daniel H Wiseman; Syed M Baker; Arundhati V Dongre; Kristian Gurashi; Joanna A Storer; Tim Cp Somervaille; Kiran Batta
Journal:  EBioMedicine       Date:  2020-08-04       Impact factor: 8.143

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.